Therapeutic Efficiency and Response to 177Lu-EB-PSMA-617 in Comparison to 177Lu-PSMA-617 in Patients With mCRPC
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
In recent years, quite a few studies have demonstrated the possibility of 177Lu-PSMA-617
therapy as a viable treatment option in metastatic castration resistant prostate cancer
(mCRPC), which has been shown desired effect. To increase tumor accumulation and retention
for radioligand therapy, and reduce dosage of 177Lu, we conjugated a truncated Evans blue
(EB) molecule and DOTA chelator onto PSMA-617 (EB-PSMA-617) and labeled it with 177Lu. This
study is designed to assess the efficiency and response to 177Lu-EB-PSMA-617 (50mCi) in
comparison to 177Lu-PSMA-617 (200mCi) in patients with mCRPC.